Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The potential of combining pyrimethamine with venetoclax in HMA-resistant MDS

Aditi Shastri • 4 May 2023
MDS 2023
Myelodysplastic Syndromes Pyrimethamine Venetoclax

Aditi Shastri, MBBS, Albert Einstein College of Medicine, New York City, NY, comments on the results of a study that showed synergy between pyrimethamine and venetoclax in pre-clinical models of hypomethylating agent (HMA)-resistant myelodysplastic syndromes (MDS). This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Aditi Shastri

2:21
Potential MDS targets beyond HMAs
Aditi Shastri • 8 Dec 2023
2:25
The impact of exposure to particulate matter on survival outcomes of patients with multiple myeloma
Aditi Shastri • 8 Dec 2023
1:36
KT-333: a first-in-class STAT3 degrader
Aditi Shastri • 8 Dec 2023
1:41
Pursuing combination therapies to overcome single-agent HMA failure in patients with MDS
Aditi Shastri • 4 May 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals